Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06937177 · ClinicalTrials.gov registry record · Phase 2
Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Metastatic Colorectal Cancer Undergoing Chemotherapy
A Phase 2 study of Cancer Weight Loss, sponsored by Endevica Bio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 17
- Study locations
NCT06937177: Recruiting Phase 2 study of Cancer Weight Loss, sponsored by Endevica Bio.
NCT06937177 is a Phase 2 study of Cancer Weight Loss that is actively recruiting participants, run by Endevica Bio. The registered enrollment target is 120 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower). The trial reports 17 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06937177, a Phase 2 study of Cancer Weight Loss, is actively recruiting participants, sponsored by Endevica Bio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled study of B07, administered daily by subcutaneous (SC) injection, in up to 120 patients with newly diagnosed metastatic colorectal cancer. This study will evaluate different doses of B07 on weight, body composition and BMI in patients with sub-optimal BMIs (≤ 29 kg/m\^2). Treatment will start at the second cycle of first-line cancer chemotherapy and continue for 12-weeks with the goal of maintaining body weight and muscle mass in patients undergoing chemotherapy relative to control.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TCMCB07
Study Locations (17)
Florida
- Investigative Site - Hialeah
- Investigative Site - Margate
- Investigative Site - Miami Beach
- Investigative Site - Tamarac
California
- Investigative Site - Los Angeles
- Investigative Site - Los Angeles
Nebraska
- Investigative Site - Lincoln
- Investigative Site - Omaha
Texas
- Investigative Site - Kingwood
- Investigative Site - Laredo
Arizona
- Investigative Site - Tucson
Georgia
- Investigative Site - Atlanta
Kansas
- Investigative Site - Wichita
Michigan
- Investigative Site - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What NCT06937177 shows while recruiting
NCT06937177 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower).
The record links to 1 condition, with Cancer Weight Loss appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06937177 lists 17 locations in 11 states (Florida, California, Nebraska).
Frequently Asked Questions
What is clinical trial NCT06937177 about?
NCT06937177 is a clinical study titled "Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Metastatic Colorectal Cancer Undergoing Chemotherapy". This is a randomized, double-blind, placebo-controlled study of B07, administered daily by subcutaneous (SC) injection, in up to 120 patients with newly diagnosed metastatic colorectal cancer. This study will evaluate different doses of B07 on weight, body composition and BMI in patients with sub-op...
What is the current status of trial NCT06937177?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-04-28. Estimated completion is 2026-09.
What conditions does trial NCT06937177 study?
This clinical trial studies the following conditions: Cancer Weight Loss.
What interventions are being tested in trial NCT06937177?
The interventions under investigation include: Placebo (DRUG), TCMCB07 (DRUG).
Who is sponsoring clinical trial NCT06937177?
This trial is sponsored by Endevica Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06937177 being conducted?
This trial has 17 study locations across Arizona, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06937177's enrollment target sits among peer trials
120 569th of 2000 higher than 1,383 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI